Arch Biopartners (TSXV:ARCH; OTCBB:ACHFF) announced the good manufacturing practice (GMP) production campaign for AB569 has advanced to the GMP glass vial filling stage.
As quoted in the press release:

AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients as well as many other indications.
AB569 is a potential stand alone or complementary treatment to existing and emerging standard of care therapies for CF and COPD patients that have reduced lung function due to multi-drug resistant bacterial infections.

Click here to read the full press release.

Source: www.marketwired.com